Get the app
Insights · Patient empowerment

Preparing your next AOM consultation: a 10-minute, evidence-based checklist.

8 min read Published 4 May 2026

This article is general medical information, not medical advice. It is written for patients to use before a consultation. It is not a script for the physician, and it does not replace the structured clinical assessment your physician will conduct.

TL;DR

An obesity consultation is short. The systematic review by Irving and colleagues across 67 countries documents that primary care consultations last under 5 minutes for about half of the world's population, and rarely exceed 15 minutes anywhere except a few high-resource systems.1 If you are on an anti-obesity medication (AOM), the most useful thing you can do for your physician is to arrive prepared: a short structured note (current dose and last injection date, a symptom log with severity and triggers, weight trajectory if measured, relevant labs, top 3 questions, and any red flag clearly flagged at the top). This article gives you a practical checklist to bring to your next consultation, grounded in NICE NG246, the Endocrine Society 2015 guideline and the realities of short-slot care.

1. Why preparation matters: the 10-minute reality

Short consultations are not a sign that your physician does not care; they are a structural feature of most healthcare systems. Irving and colleagues (BMJ Open 2017) systematically reviewed 67 countries and 28.5 million consultations and reported lengths ranging from 48 seconds in Bangladesh to 22.5 minutes in Sweden. Eighteen countries representing about half of the global population had average consultation times of 5 minutes or less.1 In Western Europe, primary care consultation length spans roughly 8 to 16 minutes (UK around 9 minutes, Germany and Spain shorter, France around 16 minutes, Sweden the longest at 22.5 minutes).

The arithmetic is unforgiving for an obesity consultation. In 10 to 15 minutes, the physician needs to review your weight trajectory, ask about side effects, check for red flags, examine you if relevant, look at labs, decide on titration, write a prescription, document the encounter, and answer your questions. If you arrive without structure, the consultation reactively bounces between topics. If you arrive with a one-page summary, the consultation can do real clinical work. This is patient empowerment in the most practical sense: not a posture, a workflow.

2. Bring structured information, not stories

The single biggest lift you can give your physician is to convert your last weeks of experience into a short structured note. Five elements are enough.

Current dose and date of last injection. Not "I started Wegovy a few months ago", but "Semaglutide 1.7 mg weekly, last injection Tuesday 28 April, started 0.25 mg on 12 January, escalated as planned, no dose missed". Drug, dose, frequency, last administration, timeline. This single line saves three minutes of back-and-forth.

A symptom log with severity and triggers. For each side effect: what it is, how often, how severe (0 to 10 scale), what makes it better or worse, what dose you were on when it started. AOM gastrointestinal side effects are most intense during dose escalation and usually fade.4 Knowing exactly when something started, in relation to which dose, is what makes the symptom interpretable.

Weight trajectory if measured. Bring a weekly or biweekly timeline, not daily. If you do not weigh yourself, tell your physician why, so they do not assume avoidance. The Endocrine Society 2015 guideline emphasises that weight is one outcome among several (cardiometabolic markers, function, quality of life), not the only one.3

Relevant labs if available. Full blood count, HbA1c, lipid panel, liver and kidney function, vitamin B12 if at risk: bring the printed result or have it accessible on your phone.

Your top 3 questions, written down. Three, not ten. The discipline of choosing three forces you to identify what really matters.

3. The 5-bullet mental checklist to bring

This 5-line checklist is a Boli synthesis: each element is supported by NICE NG246 monitoring guidance, the Endocrine Society 2015 response-assessment criteria, and the GCC-CSO/FORCE 2026 patient-information recommendations (Avis n°13).5

Before your next AOM consultation, prepare these five lines:
  • 1. My current treatment line: drug, dose, weekly schedule, last injection date, doses missed in the last 4 weeks.
  • 2. My side effects this period: what, severity (0 to 10), frequency, link to dose if any, what helped.
  • 3. My trajectory: weight if measured (with dates), waist if measured, how clothes fit, energy, sleep.
  • 4. Any red flag: severe abdominal pain, persistent vomiting, mood changes, gallbladder symptoms, vision changes (flag at the very start of the consultation).
  • 5. My top 3 questions: written, in order of importance.

4. Surface red flags first, not last

The most common preparation mistake is to leave the alarming symptom for the end of the consultation, when the prescription is already written and the door is half open. Open the consultation with red flags, not pleasantries.

The signals that warrant being said in the first 60 seconds:

  • Severe, persistent abdominal pain, especially radiating to the back (rule out pancreatitis).
  • Right-upper-quadrant pain after meals, jaundice, dark urine (rule out gallbladder disease, more frequent with rapid weight loss).
  • Vomiting that prevents you from drinking (dehydration, possible electrolyte issues).
  • Mood changes, persistent low mood, or any suicidal ideation. This is medically important. The signal needs to be heard early.
  • Vision changes, especially in patients with type 2 diabetes.
  • Severe persistent fatigue, paresthesia or cognitive changes (could be micronutrient-related; see our article on GLP-1 and vitamin B12).

Phrase it neutrally and factually: "Before we discuss the rest, I want to flag one thing that worries me." Physicians appreciate that framing, and it protects you from a half-attended discussion at the end.

5. Discuss titration and the plateau honestly

Titration is rarely linear. The drug SmPCs and the NICE technology appraisals for tirzepatide (TA1026), semaglutide (TA875) and liraglutide (TA664) all allow dose-hold or step-down based on tolerability, and NICE NG246 frames the prescribing decision as one to be made with the patient (recommendation 1.17.3).2 The Endocrine Society 2015 guideline (recommendation 1.6) supports dose escalation based on efficacy and tolerability, and frames the broader prescribing process as a shared decision.3 If you are at a dose that is just barely tolerable, say so before the physician moves you up. If you are at a dose where side effects have settled and the trajectory is reasonable, hold may be the right answer.

The plateau is the other recurring topic. The 3-month mark is the early response-assessment window: meaningful loss by then signals the medication is working. The actual plateau typically arrives later, after 9 to 15 months of weight loss (in the STEP and SURMOUNT trials, weight loss continued to roughly week 60-72 before plateauing). This is biologically expected, not a sign of failure. The clinical question becomes: is this an acceptable response, given the cardiometabolic risk profile and the side effect cost? For more on the plateau pattern, see our article on GLP-1 plateau and rebound.

6. The mental load is part of the clinical picture

Some of the most important data your physician needs is not on a graph. It is in the lived experience of being on an AOM month after month: the food anxiety, the social complications around meals, the changing body image, the fatigue of explaining your treatment to people who think it is "the easy way out", the worry about stopping. This is not soft material; it directly affects adherence, which is one of the largest determinants of clinical outcome on AOMs.

If you do not name the mental load explicitly, the consultation will not address it. Suggested phrasing: "I want to flag that the psychological side of being on this medication is heavier than I expected. Can we talk about it for a minute?" That sentence opens the door. Many physicians will refer to a psychologist or to peer support if you make the request explicit. For more, see our article on the mental load of being on an AOM.

7. The unspoken topic: stopping

Anti-obesity medications are increasingly framed as long-term therapies, on the same logic as antihypertensives or statins: stop the medication, lose much of the benefit. Trial extension data (STEP 1 extension, Wilding 2022; STEP 4, Rubino 2021) confirm substantial weight regain within 12 months of discontinuation in most patients.67 That said, life events, side effects, supply issues, fertility plans or financial constraints sometimes require stopping. The clinical reality is that how you stop matters: structured tapering, planning the months that follow, agreeing on a re-introduction threshold, all reduce the abruptness of the rebound.

It is legitimate, even useful, to bring this topic up before you have decided to stop. Ask: "If at some point I need to stop this treatment, how would we plan it?" The conversation will reframe the medication as a managed long-term tool rather than a switch you flip alone in your kitchen.

8. Shared decision-making is the gold standard, not the exception

Both NICE NG246 (recommendation 1.17.3) and the Endocrine Society 2015 guideline endorse the principle of shared decision-making, and the GCC-CSO/FORCE 2026 position paper makes this explicit for AOMs: AOM initiation, monitoring and stopping should be anchored in a shared medical decision (Avis n°2 and n°3 of the working group).235 What it looks like in a 10-minute consultation:

  • The physician presents the options, the evidence and the trade-offs.
  • You name your priorities (weight loss magnitude, tolerability, cardiovascular protection, cost).
  • You converge on a plan, with explicit criteria for what would change it.
  • You both write down the plan in a way you will remember next time.

This is harder than it sounds. It is also the single highest-leverage thing you can do for the long-term success of your treatment. Bring the checklist; ask the physician to write the plan in plain language; leave with the four things you agreed.

Boli Care turns the months between consultations into a structured, physician-readable record. Dose-aligned symptom tracking, plain-language education, a one-page summary your physician can read in 30 seconds.

Get early access For physicians

References

  1. Irving G, Neves AL, Dambha-Miller H, Oishi A, Tagashira H, Verho A, Holden J. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open 2017;7(10):e017902. doi:10.1136/bmjopen-2017-017902. PMID 29118053.
  2. National Institute for Health and Care Excellence. Overweight and obesity management. NICE guideline NG246. London: NICE; published 14 January 2025; last reviewed 8 January 2026. www.nice.org.uk/guidance/ng246.
  3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2015;100(2):342-362. doi:10.1210/jc.2014-3415. PMID 25590212.
  4. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
  5. Aron-Wisnewsky J, Disse E, et al. Pharmacological treatment of obesity in adults: position statement of the GCC-CSO and FORCE working groups. Medecine des Maladies Metaboliques 2025. doi:10.1016/j.mmm.2025.10.003.
  6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.
  7. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224. PMID 33755728.

Related insights